Background
==========

Agranulocytosis means the absence of granulocytes, although this term is often used to indicate severe degrees of neutropenia \[[@b1-amjcaserep-19-1053],[@b2-amjcaserep-19-1053]\]. It can be linked to several causes and drug-induced agranulocytosis is a serious adverse event \[[@b2-amjcaserep-19-1053]\]. Among noncytostatic drugs, some antibiotics can cause agranulocytosis, with a mortality of 5--10% \[[@b1-amjcaserep-19-1053],[@b3-amjcaserep-19-1053]\].

Vancomycin was isolated from Streptomyces orientalis on the island of Borneo by Kornfield. In 1958, in the absence of an effective alternative, vancomycin was immediately approved for clinical use \[[@b4-amjcaserep-19-1053]\]. Vancomycin has been used for decades to treat infections by Gram-positive bacteria, particularly those caused by methicillin-resistant Staphylococcus aureus (MRSA) \[[@b5-amjcaserep-19-1053],[@b6-amjcaserep-19-1053]\].

The first 2 reports of vancomycin-induced agranulocytosis were published by Dangerfield and colleagues in 1960, shortly after the introduction of vancomycin into clinical practice \[[@b3-amjcaserep-19-1053],[@b7-amjcaserep-19-1053]\]. The pathogenesis of this complication has not been elucidated. The available data support the hypothesis of a peripheral mechanism mediated by antibodies and direct toxicity to the bone marrow \[[@b3-amjcaserep-19-1053],[@b8-amjcaserep-19-1053],[@b9-amjcaserep-19-1053]\].

We present the case of a patient with a diagnosis of infective endocarditis treated with vancomycin who developed agranulocytosis, with positivity of antineutrophil cytoplasm antibodies (ANCA) simultaneous to neutropenia.

Case Report
===========

A 38-year-old male patient, with a history of diabetes mellitus type 2 without treatment, was admitted for an abscess in the right kidney. The abscess was drained, and a culture of the surgical material was obtained, and a blood culture growth identified MRSA with a minimum inhibitory concentration (MIC) to vancomycin of 1 ug/mL. Intravenous vancomycin was started.

At admission the patient's serum glycemia was 135 mg/dL, glycosylated hemoglobin 7%, and serum sodium, potassium, creatinine, and urea were normal.

A transesophageal echocardiogram showed a mobile homogeneous mass with regular edges of 10×7 mm compatible with vegetation on the posterior leaflet of the mitral valve. With the diagnosis of infective endocarditis on a native mitral valve, he continued with vancomycin. Measurements of plasmatic vancomycin levels were: 20 ug/mL, 15 mcg/mL and 15 mcg/mL, with 4.5 grams and 4 grams per day of vancomycin, respectively.

The evolution was favorable, without cardiovascular complications and the control blood cultures were negative on the third day of antibiotics. On day 28 of treatment, a decrease in neutrophil count was detected. Neutropenia was progressive and accentuated on days 30 and 31 up to a value of 60 neutrophils per mm^3^ and no changes in the monocyte count was observed ([Table 1](#t1-amjcaserep-19-1053){ref-type="table"}). The medications used in the patient were vancomycin, prophylactic sodium heparin, omeprazole, insulin, and paracetamol.

Due to the possibility of neutropenia induced by drugs, the Naranjo algorithm was applied, which showed a probable adverse effect (7/10) in favor of vancomycin. The peripheral blood smear showed absence of granulocytes ([Figure 1](#f1-amjcaserep-19-1053){ref-type="fig"}), and the bone marrow examination showed normality of the precursors of the 3 series.

During neutropenic period, atypical positive ANCA (title 1/80) was detected by indirect immunofluorescence. Vancomycin was changed to daptomycin and 2 subcutaneous doses of granulocyte colony-stimulating factor (G-CSF) at 60 MU was indicated. The granulocyte count was normalized on the second day of vancomycin withdrawal. Two months after the event, the ANCA determination was negative.

Discussion
==========

Drug-induced agranulocytosis is a serious entity that implies an increased risk of infections \[[@b3-amjcaserep-19-1053]\]. Agranulocytosis or severe neutropenia is defined by an absolute neutrophil count \<500/mm^3^ \[[@b1-amjcaserep-19-1053],[@b2-amjcaserep-19-1053]\]. In Europe, the annual incidence of drug-induced agranulocytosis ranges from 1.6 to 9.2 cases per million population \[[@b2-amjcaserep-19-1053]\]. Mortality rates of agranulocytosis induced by non-chemotherapeutic drugs were reported up to 16% in a retrospective review. In cases of agranulocytosis caused by antibiotics, mortality reported is around 5% \[[@b2-amjcaserep-19-1053],[@b3-amjcaserep-19-1053]\].

Despite an extensive list of medications that cause neutropenia, only propylthiouracil, methimazole, cocaine/levamisole, minocycline, and hydralazine were associated with ANCA and neutropenia \[[@b8-amjcaserep-19-1053],[@b10-amjcaserep-19-1053]\]

Vancomycin is used to treat MRSA infections and patients with penicillin allergy. \[[@b5-amjcaserep-19-1053],[@b6-amjcaserep-19-1053],[@b11-amjcaserep-19-1053]\], several weeks of therapy with this antibiotic are required in infections such as endocarditis and chronic osteomyelitis \[[@b9-amjcaserep-19-1053],[@b11-amjcaserep-19-1053]\]. The adverse reactions to vancomycin include fever, red man syndrome, nephrotoxicity, ototoxicity, and rarely neutropenia. Retrospective analyses in hospitalized patients have estimated that the incidence of vancomycin induced neutropenia is 2% \[[@b4-amjcaserep-19-1053],[@b6-amjcaserep-19-1053],[@b12-amjcaserep-19-1053]\].

In a retrospective study that included 114 patients treated with vancomycin, 3.5% had severe neutropenia, and this was presented on day 26 (±15 days) after the start of treatment. There was no association between the total dose of vancomycin and its serum concentrations with the development of neutropenia \[[@b9-amjcaserep-19-1053]\]. In a review by Black et al. \[[@b3-amjcaserep-19-1053]\] and in a review by Segarra-Newnham and Tagoff \[[@b5-amjcaserep-19-1053]\], vancomycin-induced neutropenia was associated with a therapy lasting more than 7 days, with most cases appearing after day 20 of treatment. The neutrophil count normalizes, usually, in the first week after the suspension of vancomycin \[[@b5-amjcaserep-19-1053],[@b13-amjcaserep-19-1053]\].

The specific mechanisms behind the development of this complication have not been fully elucidated, although the hypotheses include immune-mediated neutropenia and direct toxicity of bone marrow \[[@b3-amjcaserep-19-1053],[@b6-amjcaserep-19-1053],[@b10-amjcaserep-19-1053],[@b14-amjcaserep-19-1053]\]. The development of antineutrophil antibodies, and more rarely ANCA supports the immune origin of agranulocytosis by drugs \[[@b5-amjcaserep-19-1053],[@b9-amjcaserep-19-1053],[@b10-amjcaserep-19-1053],[@b15-amjcaserep-19-1053],[@b16-amjcaserep-19-1053]\].

However, the direct role of the ANCA in the development of neutropenia is not entirely clear. The migration of cytoplasmic antigens proteinase 3 (PR3), myeloperoxidase (MPO), and cathepsin G to the neutrophil cell surface promoted by endogenous pyrogens, allow exposure to the immune system \[[@b8-amjcaserep-19-1053],[@b10-amjcaserep-19-1053]\]. Other mechanisms possibly involved are suppression of granulocytes production, complement dependent cytotoxicity, and agglutination of neutrophils by antineutrophil antibodies \[[@b10-amjcaserep-19-1053],[@b17-amjcaserep-19-1053]\].

Akamizu et al. performed *in vitro* cytotoxicity tests in serum of a patient with neutropenia and ANCA positive secondary to propylthiouracil, demonstrating that ANCA lysed neutrophils through a complement-dependent mechanism but not by antibody dependent cellular cytotoxicity \[[@b8-amjcaserep-19-1053]\].

Grayson et al. reported a case of vasculitis ANCA-associated autoimmune neutropenia with specificity against PR3 and MPO. They found only 24 cases in the literature of neutropenia associated with ANCA secondary to drugs, none of which was vancomycin \[[@b10-amjcaserep-19-1053]\].

As for the direct bone marrow cytotoxic effect, there are also arguments against it, such as the time it takes to develop neutropenia induced by vancomycin and the lack of a dose dependent effect on the neutrophil count \[[@b5-amjcaserep-19-1053],[@b18-amjcaserep-19-1053]\]. In addition, the rapid recovery of neutrophils after stopping the drug or administering G-CSF suggests that the myeloid bone marrow precursors are intact \[[@b14-amjcaserep-19-1053]\].

In our case, there was no mechanism of bone marrow toxicity due to the presence of normal myeloid precursors in bone marrow examination. We believe that ANCA may have intervened in agranulocytosis, since they were detected during neutropenia and not after vancomycin suspension. The rapid recovery of granulocytes after the suspension of the antibiotic is an element in favor of vancomycin as a causative agent \[[@b5-amjcaserep-19-1053],[@b6-amjcaserep-19-1053],[@b13-amjcaserep-19-1053]\]. The application of a method that considers causality of an adverse drug reaction, such as the Naranjo algorithm, is a useful and simple tool for these cases \[[@b19-amjcaserep-19-1053]\].

As part of the treatment of agranulocytosis, G-CSF can be used since it shortens the duration of neutropenia and implies fewer risks of infections and fatal complications \[[@b1-amjcaserep-19-1053],[@b2-amjcaserep-19-1053],[@b11-amjcaserep-19-1053],[@b14-amjcaserep-19-1053],[@b20-amjcaserep-19-1053]\].

Regarding the antibiotic scheme, European and American guidelines for infective endocarditis recommends daptomycin as an alternative to vancomycin \[[@b21-amjcaserep-19-1053],[@b22-amjcaserep-19-1053]\].

Conclusions
===========

The agranulocytosis induced by vancomycin is a known but infrequent adverse effect this drug. Usually it occurs after day 12 of treatment. In our case, like in most reported cases, it is caused by an immune-mediated mechanism and among the possible immune mechanisms involved ANCAs could have a pathogenic role. However, there are few previous reports that link ANCA with vancomycin-induced agranulocytosis. More studies are needed to determine the pathogenic mechanism of agranulocytosis mediated by ANCA.

The treatment of agranulocytosis by vancomycin involves the suspension of this antibiotic and the administration of an alternative agent, together with G-CSF administration. It is recommended to monitor the hematological parameters at least once a week in patients receiving prolonged intravenous vancomycin therapy.
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###### 

Leukocyte count evolution.

  **Cells/mm^3^**   **Days of treatment**                                                    
  ----------------- ----------------------- -------- ------- ------- ------- ------- ------- -------
  Leucocytes        14.890                  10.200   6.310   3.990   4.580   3.790   3.700   8.140
  Neutrophils       12.120                  7.750    3.670   1.780   620     210     60      4.780
  Lymphocytes       1.790                   1.520    1830    1.430   3.080   2.370   2.300   2.180
  Monocytes         890                     880      700     780     850     1.190   1.340   1.180
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